IQVIA Holdings Inc. (NYSE:IQV) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of IQVIA Holdings Inc. (NYSE:IQV) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-one research firms that are presently covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation, sixteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $249.05.

IQV has been the subject of several research analyst reports. William Blair reissued an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Truist Financial reissued a “buy” rating and set a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a report on Monday, February 10th. BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Robert W. Baird lowered their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Finally, StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th.

IQVIA Trading Up 0.9 %

Shares of IQV stock opened at $185.85 on Monday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA has a fifty-two week low of $179.28 and a fifty-two week high of $254.80. The stock has a market capitalization of $32.77 billion, a P/E ratio of 24.78, a P/E/G ratio of 1.99 and a beta of 1.50. The stock has a 50-day simple moving average of $194.94 and a 200 day simple moving average of $208.73.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, sell-side analysts expect that IQVIA will post 10.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On IQVIA

Several institutional investors have recently bought and sold shares of IQV. Smith Group Asset Management LLC bought a new stake in shares of IQVIA during the fourth quarter worth $1,616,000. Nordea Investment Management AB grew its stake in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares during the period. Hickory Asset Management Inc. acquired a new position in IQVIA in the fourth quarter valued at about $941,000. Fifth Third Bancorp boosted its position in shares of IQVIA by 13.0% during the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after buying an additional 1,521 shares during the period. Finally, Graphene Investments SAS boosted its position in shares of IQVIA by 22.0% during the fourth quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock worth $2,948,000 after buying an additional 2,700 shares during the period. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.